Skip to content
Combined Shape
Created with Sketch.
Page 1
Created with Sketch.
Page 1
Created with Sketch.
COVID-19
EyewireTV
Stocks
Interests
Cataract and Refractive
Eye-Grey
Created with Sketch.
Glaucoma
Gauge-Grey
Created with Sketch.
Healthcare
Cross-Grey
Created with Sketch.
Optometry
Laser-Grey
Created with Sketch.
Product Approvals
Gear-Grey
Created with Sketch.
Retina
Laser-Grey
Created with Sketch.
More
Events
Subscribe
About
Send a Tip
Advertising
Privacy Policy
COVID-19
EyewireTV
Stocks
Interests
Cataract and Refractive
Eye-Grey
Created with Sketch.
Glaucoma
Gauge-Grey
Created with Sketch.
Healthcare
Cross-Grey
Created with Sketch.
Optometry
Laser-Grey
Created with Sketch.
Product Approvals
Gear-Grey
Created with Sketch.
Retina
Laser-Grey
Created with Sketch.
Events
About
Send a Tip
Advertising
Privacy Policy
Page 1
Created with Sketch.
OCS-01
10.05.20
Oculis Announces Presentation of Positive Results From Phase 2 Trial of OCS-01 in Patients With Diabetic Macular Edema (DME)
Source: Oculis
07.27.20
Oculis Announces Successful End-of-Phase 2 Meeting with the FDA for OCS-01 in Two Ophthalmology Indications
Source: Oculis
05.18.20
Oculis Reports Topline Data From Phase 2 Trial With OCS-01 for Treating Inflammation and Pain Following Cataract Surgery
Source: Oculis
05.07.20
Oculis to Present Results From Its Phase 2 Trial of OCS-01 for Inflammation and Pain Following Cataract Surgery
Source: Oculis
02.10.20
Oculis Announces Positive OCS-01 Phase 2 Data in Patients with Diabetic Macular Edema (DME)
Source: Oculis
10.07.19
Oculis Announces Dosing of First Patient in Randomized Phase 2b (SKYGGN) Clinical Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery
Source: Oculis
01.04.19
Oculis Raises $15.7 Million to Advance Development of Novel Topical Treatments for Ophthalmic Diseases
Source: Oculis
View more stories
Home
Menu
Share